Advances in viral oncolytics for treatment of multiple myeloma – a focused review

Sarwar, Ayesha; Hashim, Laila; Faisal, Muhammad Salman; Haider, Mobeen Zaka; Ahmed, Zahoor; Ahmed, Tehniat Faraz; Shahzad, Moazzam; Ansar, Iqraa; Ali, Sundas; Aslam, Muhammad; Anwer, Faiz

doi:10.1080/17474086.2021.1972802

Cited by 4 publications

(3 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It needs more research for exploration. [100] The reovirus is a double-stranded RNA virus that is around 85 nm in diameter. [99] The reovirus usually produces mild or asymptomatic symptoms, such as fever, vomiting, and diarrhea.…”

Section: Other Virusmentioning

confidence: 99%

Engineering Microorganisms for Cancer Immunotherapy

Liu,

Yu,

Rong

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Cancer immunotherapy presents a promising approach to fight against cancer by utilizing the immune system. Recently, engineered microorganisms have emerged as a potential strategy in cancer immunotherapy. These microorganisms, including bacteria and viruses, can be designed and modified using synthetic biology and genetic engineering techniques to target cancer cells and modulate the immune system. This review delves into various microorganism‐based therapies for cancer immunotherapy, encompassing strategies for enhancing efficacy while ensuring safety and ethical considerations. The development of these therapies holds immense potential in offering innovative personalized treatments for cancer.This article is protected by copyright. All rights reserved

show abstract

Section: Other Virusmentioning

confidence: 99%

Engineering Microorganisms for Cancer Immunotherapy

Liu,

Yu,

Rong

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…[ 40 , 41 ] Indeed, intratumoral administration of oncolytic virus has been used for treating various types of tumors including melanoma, glioblastoma, prostate cancer, and head and neck cancer. [ 42 – 45 ] Among them, T-Vec (Talimogene laherparepvec), a modified version of oncolytic herpes simplex I virus (HSV1), was approved by the FDA for treating metastatic melanoma in 2015. [ 46 , 47 ] T-Vec has two genes (Infected Cell Protein 34.5 (ICP34.5) and Infected Cell Protein 47 (ICP47)) removed and one gene (human granulocyte-macrophage colony-stimulating factor (GM-CSF)) added from HSV1 ( Figure 3 ).…”

Section: Living-material-based In Situ Cancer Vaccinementioning

confidence: 99%

Biomaterial‐Based In Situ Cancer Vaccines

Yang

Wang

2023

Advanced Materials

View full text Add to dashboard Cite

Cancer immunotherapies have reshaped the paradigm for cancer treatment over the past decade. Among them, therapeutic cancer vaccines that aim to modulate antigen‐presenting cells and subsequent T cell priming processes are among the first FDA‐approved cancer immunotherapies. However, despite showing benign safety profiles and the capability to generate antigen‐specific humoral and cellular responses, cancer vaccines have been limited by the modest therapeutic efficacy, especially for immunologically cold solid tumors. One key challenge lies in the identification of tumor‐specific antigens, which involves a costly and lengthy process of tumor cell isolation, DNA/RNA extraction, sequencing, mutation analysis, epitope prediction, peptide synthesis, and antigen screening. To address these issues, in situ cancer vaccines have been actively pursued to generate endogenous antigens directly from tumors and utilize the generated tumor antigens to elicit potent cytotoxic T lymphocyte (CTL) response. Biomaterials‐based in situ cancer vaccines, in particular, have achieved significant progress by taking advantage of biomaterials that can synergize antigens and adjuvants, troubleshoot delivery issues, home, and manipulate immune cells in situ. This review will provide an overview of biomaterials‐based in situ cancer vaccines, either living or artificial materials, under development or in the clinic, and discuss the design criteria for in situ cancer vaccines.

show abstract

“…Not all viruses are suitable for use as oncolytic viruses, and their selection depends on factors such as the potential pathogenicity, immunogenicity, and genes encoding the therapeutic ability of the virus ( Russell et al, 2012 ). Several oncolytic viruses are currently in use, including adenovirus (Ad; Gállego Pérez-Larraya et al, 2022 ; Nisar et al, 2022 ; Yngve et al, 2022 ), herpes simplex virus (HSV; Kawamura et al, 2022 ; Scanlan et al, 2022 ; Shayan et al, 2022 ), vaccinia virus (VV; Zhou et al, 2020 ; Yang Z. et al, 2021 ), reovirus ( Seyed-Khorrami et al, 2021 ; Yang C. et al, 2021 ), poliovirus ( Ghajar-Rahimi et al, 2022 ; Wei et al, 2022 ), coxsackie virus (CV; Lu et al, 2020 ; Sarwar et al, 2021 ), Newcastle disease virus (NDV; Chan et al, 2021 ), vesicular stomatitis virus (VSV; Sarwar et al, 2021 ), myxoma virus ( Villa et al, 2022 ), and some enteroviruses ( Xu et al, 2021 ; Kolyasnikova et al, 2023 ).…”

Section: Development Species and Research Progress Of Oncolytic Virusesmentioning

confidence: 99%

Development and application of oncolytic viruses as the nemesis of tumor cells

et al. 2023

View full text Add to dashboard Cite

Viruses and tumors are two pathologies that negatively impact human health, but what occurs when a virus encounters a tumor? A global consensus among cancer patients suggests that surgical resection, chemotherapy, radiotherapy, and other methods are the primary means to combat cancer. However, with the innovation and development of biomedical technology, tumor biotherapy (immunotherapy, molecular targeted therapy, gene therapy, oncolytic virus therapy, etc.) has emerged as an alternative treatment for malignant tumors. Oncolytic viruses possess numerous anti-tumor properties, such as directly lysing tumor cells, activating anti-tumor immune responses, and improving the tumor microenvironment. Compared to traditional immunotherapy, oncolytic virus therapy offers advantages including high killing efficiency, precise targeting, and minimal side effects. Although oncolytic virus (OV) therapy was introduced as a novel approach to tumor treatment in the 19th century, its efficacy was suboptimal, limiting its widespread application. However, since the U.S. Food and Drug Administration (FDA) approved the first OV therapy drug, T-VEC, in 2015, interest in OV has grown significantly. In recent years, oncolytic virus therapy has shown increasingly promising application prospects and has become a major research focus in the field of cancer treatment. This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.

show abstract

Advances in viral oncolytics for treatment of multiple myeloma – a focused review

Cited by 4 publications

References 103 publications

Engineering Microorganisms for Cancer Immunotherapy

Engineering Microorganisms for Cancer Immunotherapy

Biomaterial‐Based In Situ Cancer Vaccines

Development and application of oncolytic viruses as the nemesis of tumor cells

Contact Info

Product

Resources

About